4.3 Article

Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives

Journal

BRAIN TOPOGRAPHY
Volume 31, Issue 6, Pages 1029-1036

Publisher

SPRINGER
DOI: 10.1007/s10548-018-0653-8

Keywords

Cortical thickness; Sub-cortical volumes; Parkinson's disease; LRRK2; GBA

Funding

  1. AbbVie pharmaceuticals
  2. National Parkinson Foundation
  3. Solvay pharmaceuticals
  4. TEVA
  5. RAFA
  6. Medtronic
  7. Novartis
  8. Medison
  9. Allergan
  10. GlaxoSmithKline
  11. Perrigo
  12. Intecpharma
  13. Israeli Science Foundation Legacy Heritage Fund
  14. Chief Scientist Department of Health, Israel
  15. ALS Association USA
  16. Kahn Foundation Israel
  17. Teva-Lundbeck
  18. UCB
  19. NeuroDerm
  20. NPF
  21. MJFF
  22. Biogen
  23. Israeli Science Foundation
  24. Israeli Ministry of Science and Technology

Ask authors/readers for more resources

Cerebral atrophy has been detected in patients with Parkinson's disease (PD) both with and without dementia, however differentiation based on genetic status has thus far not yielded robust findings. We assessed cortical thickness and subcortical volumes in a cohort of PD patients and healthy controls carriers of the G2019S mutation in the LRRK2 gene and the common GBA mutations, in an attempt to determine whether genetic status influences structural indexes. Cortical thickness and subcortical volumes were computed and compared between six groups of participants; idiopathic PD, GBA-PD, LRRK2-PD, non-manifesting non-carriers (NMNC), GBA-non-manifesting carriers (NMC) and LRRK2-NMC utilizing the FreeSurfer software program. All participants were cognitively intact based on a computerized cognitive assessment battery. Fifty-seven idiopathic PD patients, 9 LRRK2-PD, 12 GBA-PD, 49 NMNC, 41 LRRK2-NMC and 14 GBA-NMC participated in this study. Lower volumes among patients with PD compared to unaffected participants were detected in bilateral hippocampus, nucleus accumbens, caudate, thalamus, putamen and amygdala and the right pallidum (p = 0.016). PD patients demonstrated lower cortical thickness indexes in a majority of regions assessed compared with non-manifesting participants. No differences in cortical thickness and subcortical volumes were detected within each of the groups of participants based on genetic status. Mutations in the GBA and LRRK2 genes are not important determinants of cortical thickness and subcortical volumes in both patients with PD and non-manifesting participants. PD is associated with a general reduction in cortical thickness and sub-cortical atrophy even in cognitively intact patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available